Latest Articles

  • How should I manage my patient with cancer who is experiencing diarrhea while on immunotherapy?
    Rupayan Kundu, MD, Arjun Chatterjee, MD, Jessica Philpott, MD, PhD and Lucy Boyce Kennedy, MD
    Cleveland Clinic Journal of Medicine July 2025, 92 (7) 401-405; DOI: https://doi.org/10.3949/ccjm.92a.24090

    Diarrhea and colitis, which can result from infection or be complications of immune checkpoint inhibitors, require prompt evaluation so that appropriate treatment can be started.

  • Fecal microbiota transplantation: Current evidence and future directions
    Fecal microbiota transplantation: Current evidence and future directions
    Michael Cymbal, DO, Arjun Chatterjee, MD and Brian Baggott, MD
    Cleveland Clinic Journal of Medicine July 2025, 92 (7) 421-428; DOI: https://doi.org/10.3949/ccjm.92a.24107

    Fecal microbiota transplantation is recognized for effectively treating recurrent Clostridioides difficile infection, prompting further investigation into its other possible clinical applications.

  • Recreational cannabis legalization: Potential implications for individual and community health
    Taseen Alam, BA, Connor Riegal, BS, Natalie Saadeh, MD, Fernanda Gushken, MD, MS, Hannah Snyder, MD, Brenden Jenks, MD and Akhil Anand, MD
    Cleveland Clinic Journal of Medicine July 2025, 92 (7) 407-413; DOI: https://doi.org/10.3949/ccjm.92a.24086

    The authors discuss evidence on the effects of legalized recreational cannabis on overall cannabis consumption, crime, traffic safety, and individual and community health.

  • High-output heart failure from arteriovenous dialysis access: A structured approach to diagnosis and management
    Maximilian C. Volk, DO, Bianca Honnekeri, MD, Joanna Ghobrial, MD, Mazen Hanna, MD, Sanjeeb Bhattacharya, MD, Lee Kirksey, MD, J. Emanuel Finet, MD and Heba Wassif, MD, MPH
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 362-371; DOI: https://doi.org/10.3949/ccjm.92a.24114

    Arteriovenous high-output heart failure is likely underdiagnosed because many clinicians are uncertain about when and how to evaluate for it.

  • Direct oral anticoagulants: Challenging prescribing scenarios in everyday practice
    CME article
    Syed Bukhari, MD, MHA, Mohamed Ghoweba, MD, Syed Zamrak Khan, MD, Ammar Saati, MD and Marcelo Gomes, MD
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 353-361; DOI: https://doi.org/10.3949/ccjm.92a.24061

    Preapproval trials of direct oral anticoagulants excluded patients with extreme body weight and advanced kidney and liver disease and those who had undergone bariatric surgery. Cautious decision-making in these patients is warranted.

  • My adult patient’s hypercholesterolemia is not responding to statins—what’s next?
    Faaiq N. Aslam, MD, Mohamed G. Ibrahim, DO and Razvan Chirila, MD
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 347-351; DOI: https://doi.org/10.3949/ccjm.92a.24117

    Further investigation is needed when patients do not meet their target low-density lipoprotein cholesterol levels with statin therapy alone.

  • Nitrogen: The unsung hero of vascular physiology
    Adam J. Brown, MD
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 344-346; DOI: https://doi.org/10.3949/ccjm.92a.24120

    The seventh element on the periodic table—nitrogen—may not come to mind often in day-to-day medical practice, but it is more exciting than you might think.

  • IgA nephropathy: Update on pathogenesis and treatment
    IgA nephropathy: Update on pathogenesis and treatment
    Seshma Ramsawak, MD, Scott Cohen, MD, Andrea Linares, DO and Corey Cavanaugh, DO
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 373-383; DOI: https://doi.org/10.3949/ccjm.92a.24105

    Renin-angiotensin-aldosterone system inhibitors or corticosteroids remain the cornerstone of therapy, but new agents targeting the different “hits” in the pathogenesis of IgA nephropathy are being introduced.

  • Severe cutaneous reaction induced by allopurinol
    Pietro Bocchi, MD, Lorenza Terroni, MD and Corrado Pattacini, MD
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 331-333; DOI: https://doi.org/10.3949/ccjm.92a.24063

    Three weeks after starting allopurinol for gout, an 86-year-old woman presented with a maculopapular rash and painful blistering and erosions of the oral mucosa.

  • Allopurinol hypersensitivity is rare, bad, and partially avoidable, but allopurinol can still be used effectively
    Brian F. Mandell, MD, PhD
    Cleveland Clinic Journal of Medicine June 2025, 92 (6) 326-328; DOI: https://doi.org/10.3949/ccjm.92b.06025

    The shadow of the 1984 Hande et al guidelines still hangs over clinical decision-making when managing allopurinol dosing in patients with gout and chronic kidney disease.

Pages